Adverum Biotechnologies Financials
ADVM Stock | USD 6.45 0.29 4.71% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.92 | 4.1251 |
|
|
Investors should never underestimate Adverum Biotechnologies' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Adverum Biotechnologies' cash flow, debt, and profitability to make informed and accurate decisions about investing in Adverum Biotechnologies.
Net Income |
|
Adverum | Select Account or Indicator |
Understanding current and past Adverum Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adverum Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Adverum Biotechnologies' assets may result in an increase in income on the income statement.
Adverum Biotechnologies Stock Summary
Adverum Biotechnologies competes with Uniqure NV, Rocket Pharmaceuticals, Rhythm Pharmaceuticals, Solid Biosciences, and MeiraGTx Holdings. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US00773U1088 |
CUSIP | 00773U108 05337G107 00773U207 |
Location | California; U.S.A |
Business Address | 100 Cardinal Way, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | adverum.com |
Phone | 650 656 9323 |
Currency | USD - US Dollar |
Adverum Biotechnologies Key Financial Ratios
Return On Equity | -0.76 | ||||
Operating Margin | (29.22) % | ||||
Price To Sales | 128.14 X | ||||
Revenue | 3.6 M | ||||
Gross Profit | (81.68 M) |
Adverum Biotechnologies Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 222.7M | 482.6M | 439.7M | 308.4M | 173.0M | 247.9M | |
Other Current Liab | 2.6M | 9.1M | 14.8M | 3.3M | 2.1M | 3.9M | |
Other Liab | 1.4M | 48K | 1.1M | 1.0M | 942.3K | 895.2K | |
Net Debt | (33.6M) | (31.7M) | 68.8M | 38.4M | 36K | 37.8K | |
Retained Earnings | (385.0M) | (502.5M) | (648.1M) | (802.6M) | (919.8M) | (873.8M) | |
Accounts Payable | 4.1M | 2.8M | 1.4M | 2.2M | 1.9M | 1.9M | |
Cash | 65.9M | 62.4M | 34.2M | 68.4M | 75M | 78.2M | |
Other Current Assets | 9.8M | 9.4M | 6.2M | 5.0M | 6.2M | 4.4M | |
Total Liab | 47.8M | 48.2M | 123.5M | 126.9M | 89.5M | 46.9M | |
Total Current Assets | 175.9M | 434.4M | 317.1M | 190.6M | 102.8M | 97.6M | |
Other Assets | 1.0M | 1.0M | 3.5M | 3.9M | 4.5M | 4.7M | |
Net Tangible Assets | 175.0M | 434.3M | 316.2M | 181.5M | 208.7M | 256.7M | |
Capital Surpluse | 522.5M | 560.7M | 937.1M | 965.0M | 1.1B | 599.6M | |
Short Term Debt | 4.0M | 8.9M | 3.8M | 26.5M | 20.8M | 21.9M | |
Common Stock | 5K | 6K | 7K | 10K | 11.5K | 7.4K | |
Net Invested Capital | 175.0M | 434.3M | 316.2M | 181.5M | 83.5M | 79.3M | |
Net Working Capital | 156.5M | 413.6M | 295.8M | 158.3M | 77.9M | 74.0M |
Adverum Biotechnologies Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 1.6M | 250K | 7.5M | 3.6M | 4.1M | 2.8M | |
Gross Profit | 250K | (4.2M) | 2.9M | (6.5M) | (2.0M) | (1.9M) | |
Operating Income | (68.5M) | (118.0M) | (146.1M) | (157.1M) | (123.8M) | (130.0M) | |
Ebit | (68.5M) | (116.4M) | (145.5M) | (154.5M) | (118.2M) | (112.3M) | |
Research Development | 40.4M | 73.3M | 89.2M | 99.3M | 77.7M | 50.2M | |
Ebitda | (67.0M) | (112.2M) | (140.9M) | (147.9M) | (112.6M) | (107.0M) | |
Cost Of Revenue | 40.4M | 4.2M | 4.6M | 6.5M | 5.6M | 5.4M | |
Income Before Tax | (64.5M) | (116.4M) | (145.5M) | (154.5M) | (118.2M) | (124.2M) | |
Net Income | (64.5M) | (117.5M) | (145.5M) | (154.5M) | (117.2M) | (123.0M) | |
Income Tax Expense | 1.4M | 1.1M | 4.4M | 74K | (1.1M) | (1.0M) |
Adverum Biotechnologies Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (89.1M) | (3.5M) | (26.7M) | 34.2M | 6.0M | 5.1M | |
Free Cash Flow | (68.4M) | (91.1M) | (123.0M) | (119.9M) | (91.7M) | (87.1M) | |
Depreciation | 1.6M | 4.2M | 4.6M | 6.5M | 5.6M | 5.9M | |
Other Non Cash Items | 58K | 75K | (25K) | (51K) | 11.4M | 11.9M | |
Capital Expenditures | 19.2M | 11.8M | 15.1M | 11.8M | 808K | 767.6K | |
Net Income | (64.5M) | (117.5M) | (145.5M) | (154.5M) | (117.2M) | (123.0M) | |
End Period Cash Flow | 66.9M | 63.4M | 36.7M | 70.9M | 77.0M | 76.3M | |
Investments | (48.8M) | (268.3M) | 93.8M | 141.7M | 96.9M | 101.7M | |
Change To Netincome | 9.9M | 20.8M | 26.2M | 20.0M | 18.0M | 17.6M |
Adverum Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adverum Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adverum Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adverum Biotechnologies competition to find correlations between indicators driving Adverum Biotechnologies's intrinsic value. More Info.Adverum Biotechnologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Adverum Biotechnologies' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adverum Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adverum Biotechnologies Systematic Risk
Adverum Biotechnologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Adverum Biotechnologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Adverum Biotechnologies correlated with the market. If Beta is less than 0 Adverum Biotechnologies generally moves in the opposite direction as compared to the market. If Adverum Biotechnologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adverum Biotechnologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adverum Biotechnologies is generally in the same direction as the market. If Beta > 1 Adverum Biotechnologies moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Adverum Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adverum Biotechnologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adverum Biotechnologies growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Adverum Biotechnologies November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adverum Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adverum Biotechnologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adverum Biotechnologies based on widely used predictive technical indicators. In general, we focus on analyzing Adverum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adverum Biotechnologies's daily price indicators and compare them against related drivers.
Information Ratio | (0.11) | |||
Maximum Drawdown | 16.06 | |||
Value At Risk | (6.81) | |||
Potential Upside | 5.04 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.